Back to discover
Drug

Reparixin

Late-stage clinical development
ClassInterleukin-8 receptor A modulator

Also known as Reparixina, Réparixine, Reparixinum.

RxNorm480850ChEMBLCHEMBL191413UNIIU604E1NB3K
1
Active clinical trials
2
Protein targets
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Phase 2, Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Assess Efficacy and Safety of Reparixin as add-on Therapy to SoC in Acute Respiratory Distress Syndrome (RESPIRATIO)

Clinical trial2026-05-11Results posted · ClinicalTrials.gov

Phase II Study of Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium [MPN-RC 120]

Clinical trial2026-05-06Results expected Q4 2027 · ClinicalTrials.gov

Reparixin 1200 mg TID as add-on to SoC to Limit Disease Progression in Hospitalised Patients With COVID-19 and Other Community-Acquired Pneumonia. A Multicentre, Randomized, Double-blinded, Placebo-controlled, Phase III Trial (REPAVID-22)

Clinical trial2024-09-27Terminated · ClinicalTrials.gov

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2 Study to Assess Efficacy and Safety of Reparixin in Cancer Related Fatigue in Pts With Advanced / Metastatic Breast Cancer Undergoing Taxane-based Chemotherapy.

Clinical trial2024-07-01Withdrawn · ClinicalTrials.gov

A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia

Clinical trial2024-06-13Results posted · ClinicalTrials.gov

A Phase 3, Multicenter, Randomized, Double-blind, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Transplantation

Clinical trial2024-01-03Results posted · ClinicalTrials.gov

A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation

Clinical trial2023-11-02Results posted · ClinicalTrials.gov

A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Paclitaxel in Combination With Reparixin Compared to Paclitaxel Alone as Front-line Therapy for Metastatic Triple- Negative Breast Cancer (FRIDA)

Clinical trial2022-09-16Results posted · ClinicalTrials.gov

A Phase 2 Multicenter, Randomized, Open Label, Parallel Assignment, Pilot Study to Assess the Efficacy and Safety of Reparixin Following Islet Transplantation in Patients With Type 1 Diabetes Mellitus

Clinical trial2021-03-11Results posted · ClinicalTrials.gov

Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With COVID-19 Pneumonia

Clinical trial2021-02-02Terminated · ClinicalTrials.gov

A Multicenter, Open-label, Randomized Pilot Clinical Study of Efficacy and Safety of Reparixin for Prevention of Early Allograft Dysfunction in Patients Undergoing Orthotopic Liver Transplantation

Clinical trial2017-03-31Terminated · ClinicalTrials.gov

A Single Arm, Preoperative, Pilot Study to Evaluate the Safety and Biological Effects of Orally Administered Reparixin in Early Breast Cancer Patients Who Are Candidates for Surgery

Clinical trial2016-03-01Terminated · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Reparixin
Aliases & brands
ReparixinaRéparixineReparixinum
RxNorm CUI
480850
ChEMBL ID
CHEMBL191413
UNII
U604E1NB3K
Primary mechanism
Interleukin-8 receptor A modulator

Pharmacology & targets

2 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

C-X-C chemokine receptor type 1
CXCR1 · P25024
MODULATORInterleukin-8 receptor A modulator
C-X-C chemokine receptor type 2
CXCR2 · P25025
MODULATORInterleukin-8 receptor B modulator

Clinical trials

12 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
12
registered trials across all phases
LATEST COMPLETION 2025
1
Active studies
1
Recruiting
5
Late-stage (III+)
6
Completed
5
Discontinued
PHASE DISTRIBUTIONn = 12
Phase 27Phase 2 / 32Phase 33

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Reparixin 1200 mg TID as add-on to SoC to Limit Disease Progression in Hospitalised Patients With COVID-19 and Other Community-Acquired Pneumonia. A Multicentre, Randomized, Double-blinded, Placebo-controlled, Phase III Trial (REPAVID-22)

TerminatedPH IIIDompé Farmaceutici S.p.An=4142024

A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia

CompletedPH IIIDompé Farmaceutici S.p.An=2872021

Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With COVID-19 Pneumonia

TerminatedPH II/IIIDompé Farmaceutici S.p.An=562021

A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation

CompletedPH II/IIIDompé Farmaceutici S.p.An=1042018

A Phase 3, Multicenter, Randomized, Double-blind, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Transplantation

CompletedPH IIIDompé Farmaceutici S.p.An=512017

Recent completions

Trials that read out recently, adding to the completed evidence base.

Phase 2, Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Assess Efficacy and Safety of Reparixin as add-on Therapy to SoC in Acute Respiratory Distress Syndrome (RESPIRATIO)

CompletedPH IIDompé Farmaceutici S.p.An=662025

A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia

CompletedPH IIIDompé Farmaceutici S.p.An=2872021

A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Paclitaxel in Combination With Reparixin Compared to Paclitaxel Alone as Front-line Therapy for Metastatic Triple- Negative Breast Cancer (FRIDA)

CompletedPH IIDompé Farmaceutici S.p.An=1942020

A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation

CompletedPH II/IIIDompé Farmaceutici S.p.An=1042018

A Phase 3, Multicenter, Randomized, Double-blind, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Transplantation

CompletedPH IIIDompé Farmaceutici S.p.An=512017

A Phase 2 Multicenter, Randomized, Open Label, Parallel Assignment, Pilot Study to Assess the Efficacy and Safety of Reparixin Following Islet Transplantation in Patients With Type 1 Diabetes Mellitus

CompletedPH IIDompé Farmaceutici S.p.An=92013
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • ClinicalTrials.gov — clinical trials